Difference between revisions of "Colorectal cancer, BRAF-mutated"
Jump to navigation
Jump to search
| Line 47: | Line 47: | ||
|- | |- | ||
|} | |} | ||
| + | ''Note: the manuscript refers to 28-day cycles; this dosing is equivalent.'' | ||
<div class="toccolours" style="background-color:#fdcdac"> | <div class="toccolours" style="background-color:#fdcdac"> | ||
====Biomarker eligibility criteria==== | ====Biomarker eligibility criteria==== | ||
| Line 56: | Line 57: | ||
*[[Encorafenib (Braftovi)]] 300 mg PO once per day | *[[Encorafenib (Braftovi)]] 300 mg PO once per day | ||
*[[Cetuximab (Erbitux)]] as follows: | *[[Cetuximab (Erbitux)]] as follows: | ||
| − | **Cycle 1: 400 mg/m<sup>2</sup> IV over 120 minutes once on day 1 | + | **Cycle 1: 400 mg/m<sup>2</sup> IV over 120 minutes once on day 1 |
| − | **Cycle 2 onwards: 250 mg/m<sup>2</sup> IV over 60 minutes once | + | **Cycle 2 onwards: 250 mg/m<sup>2</sup> IV over 60 minutes once on day 1 |
| − | ''' | + | '''7-day cycles''' |
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
| Line 93: | Line 94: | ||
|- | |- | ||
|} | |} | ||
| + | ''Note: the manuscript refers to 28-day cycles; this dosing is equivalent.'' | ||
<div class="toccolours" style="background-color:#fdcdac"> | <div class="toccolours" style="background-color:#fdcdac"> | ||
====Biomarker eligibility criteria==== | ====Biomarker eligibility criteria==== | ||
| Line 101: | Line 103: | ||
*[[Encorafenib (Braftovi)]] 300 mg PO once per day | *[[Encorafenib (Braftovi)]] 300 mg PO once per day | ||
*[[Cetuximab (Erbitux)]] as follows: | *[[Cetuximab (Erbitux)]] as follows: | ||
| − | **Cycle 1: 400 mg/m<sup>2</sup> IV over 120 minutes once on day 1 | + | **Cycle 1: 400 mg/m<sup>2</sup> IV over 120 minutes once on day 1 |
| − | **Cycle 2 onwards: 250 mg/m<sup>2</sup> IV over 60 minutes once | + | **Cycle 2 onwards: 250 mg/m<sup>2</sup> IV over 60 minutes once on day 1 |
| − | ''' | + | '''7-day cycles''' |
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
| Line 110: | Line 112: | ||
##'''PRO analysis:''' Kopetz S, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Belani A, Zhang X, Tabernero J. Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC. ESMO Open. 2022 Jun;7(3):100477. Epub 2022 May 30. [https://doi.org/10.1016/j.esmoop.2022.100477 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271477/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35653981/ PubMed] | ##'''PRO analysis:''' Kopetz S, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Belani A, Zhang X, Tabernero J. Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC. ESMO Open. 2022 Jun;7(3):100477. Epub 2022 May 30. [https://doi.org/10.1016/j.esmoop.2022.100477 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271477/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35653981/ PubMed] | ||
#'''BREAKWATER:''' [https://clinicaltrials.gov/study/NCT04607421 NCT04607421] | #'''BREAKWATER:''' [https://clinicaltrials.gov/study/NCT04607421 NCT04607421] | ||
| + | ==FOLFIRI & Cetuximab {{#subobject:ir894c|Regimen=1}}== | ||
| + | FOLFIRI & Cetuximab: '''<u>FOL</u>'''inic acid (Leucovorin), '''<u>F</u>'''luorouracil, '''<u>IRI</u>'''notecan, Cetuximab | ||
| + | <div class="toccolours" style="background-color:#eeeeee"> | ||
| + | ===Regimen {{#subobject:ior4b2|Variant=1}}=== | ||
| + | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
| + | !style="width: 20%"|Study | ||
| + | !style="width: 20%"|Dates of enrollment | ||
| + | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
| + | !style="width: 20%"|Comparator | ||
| + | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
| + | |- | ||
| + | |[https://doi.org/10.1056/NEJMoa1908075 Kopetz et al. 2019 (BEACON CRC)] | ||
| + | |2017-2019 | ||
| + | |style="background-color:#1a9851" |Phase 3 (C) | ||
| + | |1. [[#Encorafenib_.26_Cetuximab|Encorafenib & Cetuximab]]<br>2. [[#Binimetinib.2C_Encorafenib.2C_Cetuximab|Binimetinib, Encorafenib, Cetuximab]] | ||
| + | | style="background-color:#d73027" |Inferior OS | ||
| + | |- | ||
| + | |} | ||
| + | ''Note: the manuscript refers to 28-day cycles; this dosing is equivalent. There is an error in the folinic acid dosing in the manuscript; the dose here is the one that is listed in the supplemental protocol.'' | ||
| + | <div class="toccolours" style="background-color:#fdcdac"> | ||
| + | ====Biomarker eligibility criteria==== | ||
| + | *BRAF p.V600E | ||
| + | </div> | ||
| + | <div class="toccolours" style="background-color:#b3e2cd"> | ||
| + | ====Chemotherapy==== | ||
| + | *[[Leucovorin (Folinic acid)]] 400 mg/m<sup>2</sup> IV once on day 1 | ||
| + | *[[Fluorouracil (5-FU)]] 400 mg/m<sup>2</sup> IV bolus once on day 1, then 2400 mg/m<sup>2</sup> IV continuous infusion over 46 to 48 hours, (total dose per cycle: 2800 mg/m<sup>2</sup>) | ||
| + | *[[Irinotecan (Camptosar)]] 180 mg/m<sup>2</sup> IV once on day 1 | ||
| + | ====Targeted therapy==== | ||
| + | *[[Cetuximab (Erbitux)]] as follows: | ||
| + | **Cycle 1: 400 mg/m<sup>2</sup> IV over 120 minutes once on day 1, then 250 mg/m<sup>2</sup> IV over 60 minutes once on day 8 | ||
| + | **Cycle 2 onwards: 250 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1 & 8 | ||
| + | '''14-day cycles''' | ||
| + | </div></div> | ||
| + | ===References=== | ||
| + | #'''BEACON CRC:''' Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, Wasan H, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Pfeiffer P, Orlov S, Lonardi S, Elez E, Kim TW, Schellens JHM, Guo C, Krishnan A, Dekervel J, Morris V, Calvo Ferrandiz A, Schmidt Tarpgaard L, Braun M, Gollerkeri A, Keir C, Maharry K, Pickard M, Christy-Bittel J, Anderson L, Sandor V, Tabernero J. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer. N Engl J Med. 2019 Oct 24;381(17):1632-1643. Epub 2019 Sep 30. [https://doi.org/10.1056/NEJMoa1908075 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/31566309/ PubMed] [https://clinicaltrials.gov/study/NCT02928224 NCT02928224] | ||
| + | ##'''Update:''' Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Elez E, Gollerkeri A, Maharry K, Christy-Bittel J, Kopetz S. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. J Clin Oncol. 2021 Feb 1;39(4):273-284. [https://doi.org/10.1200/jco.20.02088 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8078423/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/33503393/ PubMed] | ||
| + | ##'''PRO analysis:''' Kopetz S, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Belani A, Zhang X, Tabernero J. Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC. ESMO Open. 2022 Jun;7(3):100477. Epub 2022 May 30. [https://doi.org/10.1016/j.esmoop.2022.100477 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271477/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35653981/ PubMed] | ||
| + | ==Irinotecan & Cetuximab {{#subobject:ir894c|Regimen=1}}== | ||
| + | <div class="toccolours" style="background-color:#eeeeee"> | ||
| + | ===Regimen {{#subobject:ior4b2|Variant=1}}=== | ||
| + | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
| + | !style="width: 20%"|Study | ||
| + | !style="width: 20%"|Dates of enrollment | ||
| + | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
| + | !style="width: 20%"|Comparator | ||
| + | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
| + | |- | ||
| + | |[https://doi.org/10.1056/NEJMoa1908075 Kopetz et al. 2019 (BEACON CRC)] | ||
| + | |2017-2019 | ||
| + | |style="background-color:#1a9851" |Phase 3 (C) | ||
| + | |1. [[#Encorafenib_.26_Cetuximab|Encorafenib & Cetuximab]]<br>2. [[#Binimetinib.2C_Encorafenib.2C_Cetuximab|Binimetinib, Encorafenib, Cetuximab]] | ||
| + | | style="background-color:#d73027" |Inferior OS | ||
| + | |- | ||
| + | |} | ||
| + | ''Note: the manuscript refers to 28-day cycles; this dosing is equivalent.'' | ||
| + | <div class="toccolours" style="background-color:#fdcdac"> | ||
| + | ====Biomarker eligibility criteria==== | ||
| + | *BRAF p.V600E | ||
| + | </div> | ||
| + | <div class="toccolours" style="background-color:#b3e2cd"> | ||
| + | ====Chemotherapy==== | ||
| + | *[[Irinotecan (Camptosar)]] 180 mg/m<sup>2</sup> IV once on day 1 | ||
| + | ====Targeted therapy==== | ||
| + | *[[Cetuximab (Erbitux)]] as follows: | ||
| + | **Cycle 1: 400 mg/m<sup>2</sup> IV over 120 minutes once on day 1, then 250 mg/m<sup>2</sup> IV over 60 minutes once on day 8 | ||
| + | **Cycle 2 onwards: 250 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1 & 8 | ||
| + | '''14-day cycles''' | ||
| + | </div></div> | ||
| + | ===References=== | ||
| + | #'''BEACON CRC:''' Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, Wasan H, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Pfeiffer P, Orlov S, Lonardi S, Elez E, Kim TW, Schellens JHM, Guo C, Krishnan A, Dekervel J, Morris V, Calvo Ferrandiz A, Schmidt Tarpgaard L, Braun M, Gollerkeri A, Keir C, Maharry K, Pickard M, Christy-Bittel J, Anderson L, Sandor V, Tabernero J. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer. N Engl J Med. 2019 Oct 24;381(17):1632-1643. Epub 2019 Sep 30. [https://doi.org/10.1056/NEJMoa1908075 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/31566309/ PubMed] [https://clinicaltrials.gov/study/NCT02928224 NCT02928224] | ||
| + | ##'''Update:''' Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Elez E, Gollerkeri A, Maharry K, Christy-Bittel J, Kopetz S. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. J Clin Oncol. 2021 Feb 1;39(4):273-284. [https://doi.org/10.1200/jco.20.02088 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8078423/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/33503393/ PubMed] | ||
| + | ##'''PRO analysis:''' Kopetz S, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Belani A, Zhang X, Tabernero J. Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC. ESMO Open. 2022 Jun;7(3):100477. Epub 2022 May 30. [https://doi.org/10.1016/j.esmoop.2022.100477 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271477/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35653981/ PubMed] | ||
==Irinotecan, Vemurafenib, Cetuximab {{#subobject:aab14c|Regimen=1}}== | ==Irinotecan, Vemurafenib, Cetuximab {{#subobject:aab14c|Regimen=1}}== | ||
<div class="toccolours" style="background-color:#eeeeee"> | <div class="toccolours" style="background-color:#eeeeee"> | ||
Revision as of 20:58, 14 October 2023
| Section editor | |
|---|---|
 |
Travis Zack, MD, PhD University of California San Francisco San Francisco, CA, USA |
Note: the page has regimens specific to BRAF-mutated colon cancer.
- See the main colorectal cancer page for general regimens.
4 regimens on this page
5 variants on this page
|
Guidelines
ESMO
- 2016: Van Cutsem et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer PubMed
Older
- 2013: Labianca et al. Early Colon Cancer: ESMO Clinical Practice Guidelines PubMed
- 2013: Balmaña et al. Familial risk-colorectal cancer: ESMO Clinical Practice Guidelines PubMed
Japanese Society for Cancer of the Colon and Rectum
- 2016: Watanabe et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer PubMed
NCCN
- NCCN does not have guidelines at this granular level; please see NCCN Guidelines - Colon Cancer.
SIOG
- 2014: Papamichael et al. Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013 PubMed
Advanced or metastatic disease, second or third-line therapy
Binimetinib, Encorafenib, Cetuximab
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Kopetz et al. 2019 (BEACON CRC) | 2017-2019 | Phase 3 (E-RT-switch-ooc) | 1a. Irinotecan & Cetuximab 1b. FOLFIRI & Cetuximab |
Superior OS (co-primary endpoint) Median OS: 9 vs 5.4 mo (HR 0.52, 95% CI 0.39-0.70) |
| 2. Encorafenib & Cetuximab | Not reported |
Note: the manuscript refers to 28-day cycles; this dosing is equivalent.
Biomarker eligibility criteria
- BRAF p.V600E
Targeted therapy
- Binimetinib (Mektovi) 45 mg PO twice per day
- Encorafenib (Braftovi) 300 mg PO once per day
- Cetuximab (Erbitux) as follows:
- Cycle 1: 400 mg/m2 IV over 120 minutes once on day 1
- Cycle 2 onwards: 250 mg/m2 IV over 60 minutes once on day 1
7-day cycles
References
- BEACON CRC: Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, Wasan H, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Pfeiffer P, Orlov S, Lonardi S, Elez E, Kim TW, Schellens JHM, Guo C, Krishnan A, Dekervel J, Morris V, Calvo Ferrandiz A, Schmidt Tarpgaard L, Braun M, Gollerkeri A, Keir C, Maharry K, Pickard M, Christy-Bittel J, Anderson L, Sandor V, Tabernero J. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer. N Engl J Med. 2019 Oct 24;381(17):1632-1643. Epub 2019 Sep 30. link to original article contains dosing details in manuscript PubMed NCT02928224
- Update: Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Elez E, Gollerkeri A, Maharry K, Christy-Bittel J, Kopetz S. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. J Clin Oncol. 2021 Feb 1;39(4):273-284. link to original article link to PMC article PubMed
- PRO analysis: Kopetz S, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Belani A, Zhang X, Tabernero J. Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC. ESMO Open. 2022 Jun;7(3):100477. Epub 2022 May 30. link to original article link to PMC article PubMed
Encorafenib & Cetuximab
Regimen
| FDA-recommended dose |
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Kopetz et al. 2019 (BEACON CRC) | 2017-2019 | Phase 3 (E-RT-switch-ooc) | 1a. Irinotecan & Cetuximab 1b. FOLFIRI & Cetuximab |
Superior OS (co-primary endpoint) Median OS: 8.4 vs 5.4 mo (HR 0.60, 95% CI 0.45-0.79) |
| 2. Binimetinib, Encorafenib, Cetuximab | Not reported |
Note: the manuscript refers to 28-day cycles; this dosing is equivalent.
Biomarker eligibility criteria
- BRAF V600E
Targeted therapy
- Encorafenib (Braftovi) 300 mg PO once per day
- Cetuximab (Erbitux) as follows:
- Cycle 1: 400 mg/m2 IV over 120 minutes once on day 1
- Cycle 2 onwards: 250 mg/m2 IV over 60 minutes once on day 1
7-day cycles
References
- BEACON CRC: Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, Wasan H, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Pfeiffer P, Orlov S, Lonardi S, Elez E, Kim TW, Schellens JHM, Guo C, Krishnan A, Dekervel J, Morris V, Calvo Ferrandiz A, Schmidt Tarpgaard L, Braun M, Gollerkeri A, Keir C, Maharry K, Pickard M, Christy-Bittel J, Anderson L, Sandor V, Tabernero J. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer. N Engl J Med. 2019 Oct 24;381(17):1632-1643. Epub 2019 Sep 30. link to original article contains dosing details in manuscript PubMed NCT02928224
- Update: Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Elez E, Gollerkeri A, Maharry K, Christy-Bittel J, Kopetz S. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. J Clin Oncol. 2021 Feb 1;39(4):273-284. link to original article link to PMC article PubMed
- PRO analysis: Kopetz S, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Belani A, Zhang X, Tabernero J. Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC. ESMO Open. 2022 Jun;7(3):100477. Epub 2022 May 30. link to original article link to PMC article PubMed
- BREAKWATER: NCT04607421
FOLFIRI & Cetuximab
FOLFIRI & Cetuximab: FOLinic acid (Leucovorin), Fluorouracil, IRInotecan, Cetuximab
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Kopetz et al. 2019 (BEACON CRC) | 2017-2019 | Phase 3 (C) | 1. Encorafenib & Cetuximab 2. Binimetinib, Encorafenib, Cetuximab |
Inferior OS |
Note: the manuscript refers to 28-day cycles; this dosing is equivalent. There is an error in the folinic acid dosing in the manuscript; the dose here is the one that is listed in the supplemental protocol.
Biomarker eligibility criteria
- BRAF p.V600E
Chemotherapy
- Leucovorin (Folinic acid) 400 mg/m2 IV once on day 1
- Fluorouracil (5-FU) 400 mg/m2 IV bolus once on day 1, then 2400 mg/m2 IV continuous infusion over 46 to 48 hours, (total dose per cycle: 2800 mg/m2)
- Irinotecan (Camptosar) 180 mg/m2 IV once on day 1
Targeted therapy
- Cetuximab (Erbitux) as follows:
- Cycle 1: 400 mg/m2 IV over 120 minutes once on day 1, then 250 mg/m2 IV over 60 minutes once on day 8
- Cycle 2 onwards: 250 mg/m2 IV over 60 minutes once per day on days 1 & 8
14-day cycles
References
- BEACON CRC: Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, Wasan H, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Pfeiffer P, Orlov S, Lonardi S, Elez E, Kim TW, Schellens JHM, Guo C, Krishnan A, Dekervel J, Morris V, Calvo Ferrandiz A, Schmidt Tarpgaard L, Braun M, Gollerkeri A, Keir C, Maharry K, Pickard M, Christy-Bittel J, Anderson L, Sandor V, Tabernero J. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer. N Engl J Med. 2019 Oct 24;381(17):1632-1643. Epub 2019 Sep 30. link to original article contains dosing details in manuscript PubMed NCT02928224
- Update: Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Elez E, Gollerkeri A, Maharry K, Christy-Bittel J, Kopetz S. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. J Clin Oncol. 2021 Feb 1;39(4):273-284. link to original article link to PMC article PubMed
- PRO analysis: Kopetz S, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Belani A, Zhang X, Tabernero J. Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC. ESMO Open. 2022 Jun;7(3):100477. Epub 2022 May 30. link to original article link to PMC article PubMed
Irinotecan & Cetuximab
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Kopetz et al. 2019 (BEACON CRC) | 2017-2019 | Phase 3 (C) | 1. Encorafenib & Cetuximab 2. Binimetinib, Encorafenib, Cetuximab |
Inferior OS |
Note: the manuscript refers to 28-day cycles; this dosing is equivalent.
Biomarker eligibility criteria
- BRAF p.V600E
Chemotherapy
- Irinotecan (Camptosar) 180 mg/m2 IV once on day 1
Targeted therapy
- Cetuximab (Erbitux) as follows:
- Cycle 1: 400 mg/m2 IV over 120 minutes once on day 1, then 250 mg/m2 IV over 60 minutes once on day 8
- Cycle 2 onwards: 250 mg/m2 IV over 60 minutes once per day on days 1 & 8
14-day cycles
References
- BEACON CRC: Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, Wasan H, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Pfeiffer P, Orlov S, Lonardi S, Elez E, Kim TW, Schellens JHM, Guo C, Krishnan A, Dekervel J, Morris V, Calvo Ferrandiz A, Schmidt Tarpgaard L, Braun M, Gollerkeri A, Keir C, Maharry K, Pickard M, Christy-Bittel J, Anderson L, Sandor V, Tabernero J. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer. N Engl J Med. 2019 Oct 24;381(17):1632-1643. Epub 2019 Sep 30. link to original article contains dosing details in manuscript PubMed NCT02928224
- Update: Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Elez E, Gollerkeri A, Maharry K, Christy-Bittel J, Kopetz S. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. J Clin Oncol. 2021 Feb 1;39(4):273-284. link to original article link to PMC article PubMed
- PRO analysis: Kopetz S, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Belani A, Zhang X, Tabernero J. Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC. ESMO Open. 2022 Jun;7(3):100477. Epub 2022 May 30. link to original article link to PMC article PubMed
Irinotecan, Vemurafenib, Cetuximab
Regimen
| Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Kopetz et al. 2020 (SWOG 1406) | 2014-NR | Randomized Phase 2 (E-esc) | Irinotecan & Cetuximab | Superior PFS (primary endpoint) |
Biomarker eligibility criteria
- BRAF V600E, absence of NRAS and KRAS mutations
Chemotherapy
- Irinotecan (Camptosar) 180 mg/m2 IV once on day 1
Targeted therapy
- Vemurafenib (Zelboraf) 960 mg PO twice per day
- Cetuximab (Erbitux) 500 mg/m2 IV once on day 1
14-day cycles
References
- SWOG S1406: Kopetz S, Guthrie KA, Morris VK, Lenz HJ, Magliocco AM, Maru D, Yan Y, Lanman R, Manyam G, Hong DS, Sorokin A, Atreya CE, Diaz LA, Allegra C, Raghav KP, Wang SE, Lieu CH, McDonough SL, Philip PA, Hochster HS. Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406). J Clin Oncol. 2021 Feb 1;39(4):285-294. Epub 2020 Dec 23. link to original article contains dosing details in manuscript link to PMC article PubMed NCT02164916
Dabrafenib, Trametinib, Panitumumab
Regimen
| Study | Evidence | Efficacy |
|---|---|---|
| Awaiting publication (Study 116833) | Phase 1/2 | ORR: 26% |
Note: efficacy and dosing details are from a 2017 ASCO abstract.
Biomarker eligibility criteria
- BRAF V600E
Targeted therapy
- Dabrafenib (Tafinlar) 150 mg PO twice per day
- Trametinib (Mekinist) 2 mg PO once per day
- Panitumumab (Vectibix) 6 mg/kg IV once on day 1
14-day cycles
References
- Study 116833: NCT01750918